دورية أكاديمية
أعرض في EDS

Impact of TSPO Receptor Polymorphism on [ 18 F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders.

التفاصيل البيبلوغرافية
العنوان: Impact of TSPO Receptor Polymorphism on [ 18 F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders.
المؤلفون: Vettermann FJ; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Harris S; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Schmitt J; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Unterrainer M; Department of Radiology, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Lindner S; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Rauchmann BS; Department of Radiology, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.; Department of Psychiatry and Psychotherapy, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Palleis C; Department of Neurology, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Weidinger E; Department of Neurology, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Beyer L; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Eckenweber F; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Schuster S; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Biechele G; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Ferschmann C; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Milenkovic VM; Department of Psychiatry and Psychotherapy, University of Regensburg, 93053 Regensburg, Germany., Wetzel CH; Department of Psychiatry and Psychotherapy, University of Regensburg, 93053 Regensburg, Germany., Rupprecht R; Department of Psychiatry and Psychotherapy, University of Regensburg, 93053 Regensburg, Germany., Janowitz D; Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Buerger K; Institute for Stroke and Dementia Research, University Hospital of Munich, LMU Munich, 81377 Munich, Germany., Perneczky R; Department of Psychiatry and Psychotherapy, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College, London SW7 2AZ, UK.; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany., Höglinger GU; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.; Department of Neurology, Hannover Medical School, 30625 Hannover, Germany., Levin J; Department of Neurology, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany., Haass C; German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.; Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, LMU Munich, 82152 Planegg, Germany., Tonn JC; Department of Neurosurgery, University Hospital of Munich, 81377 Munich, Germany., Niyazi M; Department of Radiation Oncology, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany., Bartenstein P; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany., Albert NL; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany., Brendel M; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, 81377 Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany.
المصدر: Life (Basel, Switzerland) [Life (Basel)] 2021 May 26; Vol. 11 (6). Date of Electronic Publication: 2021 May 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101580444 Publication Model: Electronic Cited Medium: Print ISSN: 2075-1729 (Print) Linking ISSN: 20751729 NLM ISO Abbreviation: Life (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, 2011-
مستخلص: TSPO-PET tracers are sensitive to a single-nucleotide polymorphism (rs6971-SNP), resulting in low-, medium- and high-affinity binders (LABs, MABs and HABS), but the clinical relevance of [ 18 F]GE-180 is still unclear. We evaluated the impact of rs6971-SNP on in vivo [ 18 F]GE-180 binding in a healthy brain and in pseudo-reference tissue in neuro-oncological and neurodegenerative diseases. Standardized uptake values (SUVs) of [ 18 F]GE-180-PET were assessed using a manually drawn region of interest in the frontoparietal and cerebellar hemispheres. The SUVs were compared between the LABs, MABs and HABs in control, glioma, four-repeat tauopathy (4RT) and Alzheimer's disease (AD) subjects. Second, the SUVs were compared between the patients and controls within their rs6971-subgroups. After excluding patients with prior therapy, 24 LABs (7 control, 5 glioma, 6 4RT and 6 AD) were analyzed. Age- and sex-matched MABs (n = 38) and HABs (n = 50) were selected. The LABs had lower frontoparietal and cerebellar SUVs when compared with the MABs and HABs, but no significant difference was observed between the MABs and HABs. Within each rs6971 group, no SUV difference between the patients and controls was detected in the pseudo-reference tissues. The rs6971-SNP affects [ 18 F]GE-180 quantification, revealing lower binding in the LABs when compared to the MABs and HABs. The frontoparietal and cerebellar ROIs were successfully validated as pseudo-reference regions.
References: J Labelled Comp Radiopharm. 2014 Jan;57(1):42-8. (PMID: 24448744)
Int J Mol Sci. 2019 Jan 29;20(3):. (PMID: 30699908)
J Cereb Blood Flow Metab. 2010 Sep;30(9):1608-18. (PMID: 20424634)
Bioorg Med Chem Lett. 2012 Feb 1;22(3):1308-13. (PMID: 22244939)
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1208-1211. (PMID: 30826897)
J Nucl Med. 2018 Aug;59(8):1260-1266. (PMID: 29348317)
J Nucl Med. 2016 Feb;57(2):165-8. (PMID: 26697963)
Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2304-19. (PMID: 18828015)
Mov Disord. 2017 Jun;32(6):853-864. (PMID: 28467028)
Eur J Nucl Med Mol Imaging. 2019 Jun;46(6):1205-1207. (PMID: 30656358)
Alzheimers Dement. 2018 Apr;14(4):535-562. (PMID: 29653606)
Nat Rev Drug Discov. 2010 Dec;9(12):971-88. (PMID: 21119734)
JAMA Neurol. 2020 Nov 1;77(11):1408-1419. (PMID: 33165511)
J Neuroinflammation. 2020 Jul 13;17(1):208. (PMID: 32660586)
Curr Neurol Neurosci Rep. 2019 Apr 2;19(5):24. (PMID: 30941587)
Eur Neurol. 1999;42(4):205-10. (PMID: 10567816)
Trends Pharmacol Sci. 2006 Aug;27(8):402-9. (PMID: 16822554)
Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2201-2210. (PMID: 27349244)
J Nucl Med. 2015 Apr;56(4):512-7. (PMID: 25722450)
J Nucl Med. 2013 Dec;54(12):2125-31. (PMID: 24212976)
EJNMMI Res. 2017 Oct 26;7(1):89. (PMID: 29150726)
J Nucl Med. 2015 Sep;56(9):1359-65. (PMID: 26182966)
EJNMMI Res. 2017 Dec;7(1):48. (PMID: 28560582)
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2233-2236. (PMID: 32088848)
Mov Disord. 2021 Apr;36(4):883-894. (PMID: 33245166)
Mol Imaging Biol. 2019 Oct;21(5):935-944. (PMID: 30796709)
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1423-1431. (PMID: 29523925)
Int Rev Neurobiol. 2011;101:19-39. (PMID: 22050847)
J Nucl Med. 2011 Jan;52(1):24-32. (PMID: 21149489)
Neuroimage. 2010 Feb 15;49(4):2924-32. (PMID: 19948230)
Nat Neurosci. 2019 Feb;22(2):191-204. (PMID: 30617257)
Clin Transl Imaging. 2016;4:145-156. (PMID: 27077069)
Neuroimage. 2008 Mar 1;40(1):43-52. (PMID: 18093844)
Nucl Med Biol. 1994 May;21(4):573-81. (PMID: 9234314)
J Nucl Med. 2015 May;56(5):701-6. (PMID: 25766898)
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2230-2238. (PMID: 28821920)
J Nucl Med. 2017 Mar;58(3):484-491. (PMID: 27660144)
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):580-590. (PMID: 30244386)
Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2329-2338. (PMID: 31363804)
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2237-2241. (PMID: 32524162)
J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5. (PMID: 22008728)
J Nucl Med. 2016 Nov;57(11):1753-1759. (PMID: 27261523)
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1368-1380. (PMID: 31486876)
معلومات مُعتمدة: 421887978, 422182557, EXC 2145 SyNergy - ID 390857198 Deutsche Forschungsgemeinschaft; Manfred-Strohscheer-Stiftung Hirnliga e.V.; FTLD project NOMIS foundation
فهرسة مساهمة: Keywords: 4R-tauopathy; Alzheimer’s disease; TSPO-PET; microglia; neuro-oncology; neurodegeneration
تواريخ الأحداث: Date Created: 20210602 Latest Revision: 20231107
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC8229996
DOI: 10.3390/life11060484
PMID: 34073557
قاعدة البيانات: MEDLINE
الوصف
تدمد:2075-1729
DOI:10.3390/life11060484